Press releasePRNewswire
Ovid Therapeutics
OVID · NASDAQ
$2.36+$0.19 (+8.76%)TodayMarket closed ·
Prev close $2.17
Latest news
- NewsAvi Kapoor
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Press releaseGlobe Newswire
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
- NewsVandana Singh
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy
- Press releaseGlobe Newswire
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
Earnings Scheduled For March 18, 2026
- News
Ovid Therapeutics Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $718.000K Beat $13.333K Estimate
- Press releaseGlobe Newswire
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
- Press releaseGlobe Newswire
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
- Press releaseGlobe Newswire
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
- Press releaseGlobe Newswire
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
- Press releaseGlobe Newswire
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
- News
Reported Earlier: Ovid Therapeutics Announces Topline Results From Its Phase 1 Healthy Volunteer Study Evaluating The Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Activity Of OV329, A Next Generation GABA-AT Inhibitor Being Developed For Drug-Resistant Epilepsies; Advancing To Phase 2a For Drug-Resistant Epilepsy
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
Ovid Therapeutics Q2 EPS $(0.06) Beats $(0.16) Estimate, Sales $6.272M Beat $76.667K Estimate
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
- Press releaseBusiness Wire
Ligand Reports Second Quarter 2024 Financial Results
- Press releaseGlobe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
- Press releasePRNewswire
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
- Press releaseBusiness Wire
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
- News
The Latest Analyst Ratings For Ovid Therapeutics
- Press releaseGlobe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
- Press releaseGlobe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
- Press releaseGlobe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.